Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab With or Without Olaparib in Limited-Stage Small Cell Lung Cancer
NCT04624204Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Dec 2020
- Primary completion
- Oct 2027
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 25
01
Overview
Phase 3, randomised, double-blind trial of pembrolizumab and olaparib in small cell lung cancer (SCLC) (3 arms), sponsored by Merck & Co. Primary endpoint: Overall Survival at 82 months. Started Dec 2020; status: active, not recruiting.
02
Drugs
pembrolizumabolaparib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT04624204.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04624204.